Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD033 in advanced solid tumors
NCT04242147Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of KD033 in solid tumor (3 arms), sponsored by Sanofi. Primary endpoints: Occurrence of Dose Limiting Toxicities at 28 days and Treatment Emergent Adverse Events. Started Mar 2023; status: terminated.
02
Drugs
KD033
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04242147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242147.